Invesco Ltd. Purchases New Stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Invesco Ltd. purchased a new stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 555,607 shares of the company's stock, valued at approximately $4,128,000. Invesco Ltd. owned 1.50% of Lifecore Biomedical as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. DCF Advisers LLC raised its position in Lifecore Biomedical by 87.2% during the fourth quarter. DCF Advisers LLC now owns 539,989 shares of the company's stock valued at $4,012,000 after purchasing an additional 251,511 shares in the last quarter. 272 Capital LP raised its holdings in Lifecore Biomedical by 511.1% in the 3rd quarter. 272 Capital LP now owns 143,480 shares of the company's stock worth $707,000 after purchasing an additional 120,002 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Lifecore Biomedical by 14.7% in the fourth quarter. Geode Capital Management LLC now owns 685,746 shares of the company's stock valued at $5,097,000 after acquiring an additional 88,061 shares during the period. Rangeley Capital LLC bought a new stake in shares of Lifecore Biomedical during the 4th quarter valued at $325,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Lifecore Biomedical by 71.9% in the 4th quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company's stock worth $599,000 after purchasing an additional 33,690 shares in the last quarter. 83.36% of the stock is owned by institutional investors.

Lifecore Biomedical Trading Down 0.1 %

LFCR traded down $0.01 during trading hours on Thursday, reaching $6.75. The company's stock had a trading volume of 69,470 shares, compared to its average volume of 229,411. The stock has a market cap of $249.92 million, a PE ratio of -11.90 and a beta of 0.80. Lifecore Biomedical, Inc. has a fifty-two week low of $3.68 and a fifty-two week high of $7.99. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The business's 50-day moving average is $6.24 and its 200-day moving average is $6.39.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings data on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. As a group, equities research analysts predict that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Stephens restated an "equal weight" rating and set a $6.00 price objective on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.